Analysts Set $12.67 Price Target for Scpharmaceuticals Inc (SCPH)
Scpharmaceuticals Inc (NASDAQ:SCPH) has received a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus price objective of $12.67 for the company and are expecting that the company will post ($0.50) EPS for the current quarter, according to Zacks. Zacks has also assigned Scpharmaceuticals an industry rank of 85 out of 255 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised shares of Scpharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Friday, August 17th.
NASDAQ SCPH traded down $0.14 during midday trading on Friday, hitting $3.91. The company had a trading volume of 16,337 shares, compared to its average volume of 30,462. The company has a debt-to-equity ratio of 0.10, a quick ratio of 13.80 and a current ratio of 13.80. Scpharmaceuticals has a fifty-two week low of $3.88 and a fifty-two week high of $18.17.
Scpharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.04. Research analysts predict that Scpharmaceuticals will post -2.09 EPS for the current year.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.
Read More: Asset Allocation, Balancing Your Investments
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.